Four companies have applied to Health Canada to sell copies of Ozempic after its market exclusivity expires on Jan. 4, 2026 ...

Tesla stock rises sharply extending gains for a second day, Nvidia and Palantir shares trade higher as tech stocks bounce ...

Shares of Novo Nordisk fell sharply on Monday, after the firm published results from the latest clinical trial of its ...

Novo Nordisk said it will offer all doses of Wegovy for $499 a month to patients paying cash, a bid to reach consumers who ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Here are the most important news items that investors need to start their trading day: ...

After Zepbound-maker Eli Lilly reduced the price of the weight-loss drug, competitor Novo Nordisk has cut the price of weight ...

Novo Nordisk (NVO) warns U.S. tariffs on pharmaceuticals may lead to drug shortages & price hikes. Read more here.

Pharmaceutical manufacturer Novo Nordisk on Wednesday announced it will be offering a direct-to-patient program for uninsured and underinsured individuals to be able to pay cash for its weight ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.

A looming trade war and a high-stakes lawsuit could shake up the future of Ozempic and Wegovy--here's what's at stake.